Follow our progress in developing products that have the potential to transform the future of cancer treatment
Scroll down for all the 2017 publications
eTheRNA immunotherapies CEO to present at Bio Europe 2017
eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies based on its unique TriMix platform, announces that CEO Dirk Reyn is to present at Bio-Europe 2017 in Berlin.
The presentation will take place on Wednesday 8th November at 9:45am in the ‘Cell and gene therapy track’.
This year’s BIO-Europe conference will take place from 6-8 November at CityCube in Berlin, Germany. The conference brings together thousands of attendees from the life sciences industry and offers the greatest opportunity to meet senior licensing executives from global pharma organisations and senior management of innovative drug development and platform technology companies.
About eTheRNA immunotherapies NV
eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its multiple RNA, formulation and manufacturing technology platforms. The company is headquartered in Belgium and was established in 2013 and its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company’s ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA’s R&D pipeline can be found at https://www.etherna.be/immunotherapies-rd-pipeline/.